HomeAbout

TL;DR CNBC


Drugmaker Novartis climbs after guidance rise on sales of blockbuster drugs - TL;DR CNBC

Drugmaker Novartis climbs after guidance rise on sales of blockbuster drugs

Publishing timestamp: 2024-04-23 09:04:46


Summary

Novartis shares climbed after raising full-year guidance following better-than-expected first-quarter results, with net sales and core operating income expected to grow by high single- to low double-digit percentages. CEO highlighted solid growth across major brands and geographies, leading to raised guidance for 2024. Confidence in mid- and long-term growth outlook.


Sentiment: POSITIVE

Tickers: NOV.N-CHNVS

Keywords: biotech and pharmaceuticalshealth care industrybusinessnovartis agpharmaceuticalsearningsbusiness newsbiotechnology

Source: https://www.cnbc.com/2024/04/23/shares-of-novartis-climb-4point8percent-on-raised-guidance-better-than-expected-results.html


Developed by Leo Phan